Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531

PURPOSE: The primary objective of the Children’s Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based algorithm to assign treatment duration while maintaining...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Twist, Clare J., Schmidt, Mary Lou, Naranjo, Arlene, London, Wendy B., Tenney, Sheena C., Marachelian, Araz, Shimada, Hiroyuki, Collins, Margaret H., Esiashvili, Natia, Adkins, E. Stanton, Mattei, Peter, Handler, Michael, Katzenstein, Howard, Attiyeh, Edward, Hogarty, Michael D., Gastier-Foster, Julie, Wagner, Elizabeth, Matthay, Katherine K., Park, Julie R., Maris, John M., Cohn, Susan L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2019
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6881103/
https://ncbi.nlm.nih.gov/pubmed/31386611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00919
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi